pigs, compared with placebo, BemA decreased plasma cholesterol and LDL-C up to 40% and 61%, respectively. In LDLR −/− pigs, in which plasma cholesterol and LDL-C were 5-fold higher than in LDLR +/− pigs, BemA decreased plasma cholesterol and LDL-C up to 27% and 29%, respectively. Plasma levels of triglycerides and high-density lipoprotein cholesterol, fasting glucose and insulin, and liver lipids were unaffected by treatment in either genotype. In the aorta of LDLR +/− pigs, BemA robustly attenuated en face raised lesion area (−58%) and left anterior descending coronary artery cross-sectional lesion area (−40%). In LDLR −/− pigs, in which lesions were substantially more advanced, BemA decreased aortic lesion area (−47%) and left anterior descending coronary artery lesion area (−48%). Conclusions-In a large animal model of LDLR deficiency and atherosclerosis, long-term treatment with BemA reduces LDL-C and attenuates the development of aortic and coronary atherosclerosis in both LDLR +/− and LDLR −/− miniature pigs. Visual Overview-An online visual overview is available for this article.
levated plasma levels of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), or apolipoprotein B (ApoB) are independent risk factors for cardiovascular disease. 1, 2 Inhibitors of 3-hydroxy-3-methyl-glutaryl coenzyme A (CoA) reductase, or statins, have successfully prevented cardiovascular disease events through reductions in LDL-C, consistent with the important role of LDL-C lowering in risk reduction. 3 Despite the effectiveness of statins, new treatment strategies for further risk reduction are required. Some patients, such as those with familial hypercholesterolemia, fail to achieve LDL-C targets with statins alone, and others are either statin intolerant or tolerate only suboptimal low doses. [4] [5] [6] 
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Bempedoic acid (BemA, ESP-55016, ETC-1002) was originally identified from a series of long hydrocarbon chain diacids for its ability to inhibit fatty acid and cholesterol synthesis in vitro and in vivo. 7, 8 In rodent models, BemA prevented diet-induced elevations in plasma cholesterol and triglycerides, hepatic steatosis, insulin resistance, and obesity. [9] [10] [11] Recent studies have shown that BemA-CoA is a direct and potent competitive inhibitor of ATP-citrate lyase, consistent with increased hepatic citrate concentrations and decreased concentrations of acetyl-CoA, malonyl-CoA, and 3-hydroxy-3-methyl-glutaryl CoA in murine liver. 9 In addition, the CoA derivative of BemA was required for activity; a reaction catalyzed by the liver-specific enzyme long-chain acyl-CoA synthetase-1. 11 Early studies reported that BemA also targeted AMP-activated protein kinase, a kinase that regulates Prevention of atherosclerosis in mice by BemA is promising; however, atheroprotection in mouse models using other therapeutic interventions have not necessarily translated to humans. 13 The pig represents a large animal model of human-like lipoprotein metabolism and responds to statins and other cholesterollowering medications. 14, 15 Recently, pig models of familial hypercholesterolemia have been created in which deletion of the LDLR or overexpression of the human gain-of-function PCSK9 (proprotein convertase subtilisin/kexin type 9) D374Y mutation in Yucatan miniature pigs results in hypercholesterolemia and development of human-like atherosclerotic lesions in the aorta and coronary arteries. 16, 17 The objective of the present study was to examine the impact of long-term BemA treatment on LDL-C and atherosclerosis in LDLR-deficient Yucatan miniature pigs. The efficacy of BemA in Ldlr −/− mice 10 prompted us to include homozygous and heterozygous LDLR-deficient pigs. Pigs readily developed diet-induced hypercholesterolemia and atherosclerosis without high levels of dietary cholesterol or cholate. Treatment of both LDLR +/− and LDLR −/− pigs for 160 days with BemA significantly decreased LDL-C and attenuated the development of aortic and coronary atherosclerosis.
Materials and Methods

Animals and Diets
Male and female Yucatan miniature pigs with targeted disruption of the LDLR gene were obtained from Exemplar Genetics. 16 Twelve heterozygotes (LDLR Table in the online-only Data Supplement). Pigs with initial body weights of 24 to 28 kg were housed individually in metabolic cages and were initially fed a pig chow diet (Prolab Mini-Pig Diet 5P94, PMI Nutrition, Brentwood, MO) for 2 weeks. The chow contained 10.5% of kcal from fat, 22.1% kcal from protein, and 67.3% kcal from carbohydrate. All pigs were subsequently transferred to a chow-based, fat, and cholesterol-containing diet (600 g/d) for 174 days. The high-fat, high-cholesterol (HFHC) diet provided 16%, 50%, and 34% of calories from protein, carbohydrate, and fat, respectively, and 1.2 g/d of cholesterol (0.2% of diet, 0.4 mg/kcal). The HFHC diet mimics a standard Western-type human diet. The fat ratio of 1:1:1 (polyunsaturated:monounsaturated:saturated) was achieved by mixing lard, butter, and safflower oil. 15 Body weights were measured on days 0, 28, 49, 91, and 160 of the lipid and lipoprotein study. Blood samples were obtained through surgically implanted jugular vein catheters in conscious, unrestrained animals 18 during the first 4 weeks. Subsequent samples were obtained by cranial vena cava venipuncture after anesthetization of pigs with a single intramuscular injection of tiletamine, zolazepam, zylazine, and ketamine (1.6 mg/ kg of each). Pigs were fasted for 20 to 22 hours before blood collection. The protocol was approved by the Animal Care Committee of the University of Western Ontario (protocol no. 2013-071).
Administration of Drugs and Study Protocol
BemA (ETC-1002) was obtained from Esperion Therapeutics (Plymouth, MI) in powder form. Based on initial pharmacokinetic data in pigs and the assumption that bioavailability would be similar to that found in humans, doses of 120 and 240 mg/d were used. In humans, this dose range results in optimal LDL-C responses in phase 2 studies (reviewed in Ref 12) . Oral doses of compound were placed in gelatin capsules and fed by hand, just before daily feeding. A pharmacokinetic study was performed after 14 days of the HFHC diet. LDLR +/− (n=8) and LDLR −/− (n=8) pigs were administered a single dose of BemA (120 or 240 mg). On day 15 of the of HFHC diet (study day 0), 12 LDLR +/− pigs were administered either BemA (n=4 at 120 mg/d; n=4 at 240 mg/d) or placebo (n=4), and 12 LDLR −/− pigs were administered either BemA (n=4 at 120 mg/d; n=4 at 240 mg/d) or placebo (n=4) for 160 days. Fasting blood samples were obtained weekly from day 0 to day 28 and monthly from day 56 to day 160. Animals were euthanized on day 160. The protocol is summarized in Figure 1A .
A total of 15 barrows (castrated male), 7 LDLR +/− and 8 LDLR −/− , and a total of 9 gilts (female, not bred), 5 LDLR +/− and 4 LDLR −/− , were used in the study. Pigs were randomized to drug treatment groups by age and starting body weight. Littermates, males, and females were distributed equally among placebo and drug treatment groups. There were no obvious differences between males and females for any of the study parameters examined, and thus data were not subgrouped by sex. 
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Adverse Events
Two pigs died during the study. One pig, an LDLR +/− animal at the 240 mg/d dose, presented with significant hind-limb paralysis on day 80 and had to be euthanized. Autopsy revealed a large ventricular thrombus and bacterial endocarditis because of the prolonged catheter use. This was deemed not to be drug related. The second, an LDLR −/− placebo pig, died suddenly on day 120 because of a complication of blood sampling from the cranial vena cava. The data from these 2 animals were not used for long-term lipid analyses (after day 77 and after day 120, respectively), liver analyses, or atherosclerosis studies.
Pharmacokinetic Study
A pharmacokinetic study was performed on day 14 in HFHC-fed pigs. On the day of study, fasted pigs (22 hours) were administered a dose of BemA orally by hand, along with a small amount of diet. The drug was ingested within 30 seconds, and the normal daily feed was then provided. Blood samples were obtained through the indwelling catheter at time 0, 0.5, 1, 2, 4, 6, 12, and 24 hours into tubes containing EDTA.Na 2 . Blood samples were kept on ice, immediately centrifuged (1500 rpm, 30 minutes at 4°C) to obtain plasma, and samples were stored at −80°C until analysis. Plasma concentrations of BemA (ETC-1002) and its main metabolite, ESP15228, and their respective deuterated (D4) standards (provided by Esperion) were measured by liquid chromatography-tandem mass spectrometry as described previously.
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Analytic Assays
Plasma and lipoprotein lipid analyses have been described previously. 14, 15, 18 Lipoprotein separations were performed by ultracentrifugation of fresh plasma, and samples were subsequently stored at −80°C for lipid analysis. Plasma and lipoprotein lipids were measured on a Cobas Mira S Autoanalyzer (Roche Diagnostics, Montreal, QC, Canada) using enzymatic reagents as described previously. 10 Precision testing was provided by Oneworld Accuracy (Burnaby, BC, Canada). Lipoprotein cholesterol distributions were evaluated in fresh plasma samples (50 μL) from 3 placebo, 3 BemA 120 mg/d, and 3 BemA 240 mg/d pigs of each genotype by fast protein liquid chromatography and fractions analyzed for total cholesterol as described previously. 10 Plasma lathosterol concentrations were assayed by liquid chromatography-tandem mass spectrometry as described previously. 19 Plasma glucose was measured enzymatically using a Cobas Mira S Autoanalyzer with enzymatic reagents from Roche Diagnostics. Plasma insulin concentrations were measured using a pig-specific ELISA (Alpco, Salem, NH, no. 80-INSPO-E01). Plasma levels of uric acid, total bilirubin, creatinine, creatine kinase, and alanine transaminase were performed using standard assays by the London Laboratory Services Group, Clinical Laboratories, Department of Pathology and Laboratory Medicine, London Health Sciences Centre, London, ON.
Animal Euthanasia and Tissue Analyses
Approximately 22 hours after the last dose of drug on day 160, pigs were euthanized. Pigs were pre-anesthetized with an intramuscular injection of tiletamine, zolazepam, zylazine, and ketamine (1.6 mg/ kg of each). Sedated pigs were transported to the large animal surgical suite and intubated. Isoflurane was administered at a maintenance dose of 1.5% for the duration of tissue harvesting. Blood was drawn from the cranial vena cava and put into tubes containing EDTA.Na 2 on ice. Plasma was isolated for lipid and lipoprotein analyses as described above. Liver was excised, and samples were flash frozen in liquid nitrogen and stored at −80°C. The heart and aorta (to the aortic bifurcation) were dissected from the surrounding tissue, rinsed in 1× PBS, and immersion fixed in 4% paraformaldehyde for histological examination. The paraformaldehyde was replaced at 24 and 72 hours post-sacrifice.
In liver, the concentrations of triglyceride, total cholesterol, and free cholesterol were measured using enzyme-based assays (triglyceride with glycerol blank: Trig/GB Roche/Hitachi no. 11877771 216; cholesterol: WAKO no. 439-17501; and free cholesterol WAKO no. 435-35801) in samples from lipid extracts, containing radioactive recovery standards, that were resolubilized with triton, as previously described. 10 Cholesteryl ester was calculated by difference.
Tissue mRNA Determination
RNA was isolated from aliquots of liver using Trizol reagent (Life Technologies, Mississauga, ON, Canada). Gene-specific mRNA quantification for APOB, 3-hydroxy-3-methyl-glutaryl CoA reductase (HMGCR), LDLR, sterol response element-binding factor 2 (SREBF2), SREBF1c, PCSK9, cytochrome P450 7A (CYP7A), microsomal triglyceride transfer protein (MTTP), ATP-binding cassette A1 (ABCA1), Niemann-Pick C1-like 1 (NPC1L1), solute carrier 27A (SCL27A), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was performed by quantitative real-time polymerase chain reaction on an ABI ViiA 7 Sequence Detection System (Applied Biosystems) as described previously. 10 Expression levels for each gene were normalized to GAPDH expression levels. For genes with known pig (Sus scrofa) sequences (APOB, HMGCR, SREBF2, CYP7A, MTTP, ABCA1, SCL27A, and GAPDH), primer and probe sets were designed using Primer Express 2.0 software (Applied Biosystems). 15 For LDLR and genes with unknown pig sequences (SREBF1c, NPC1L1, and PCSK9), polymerase chain reaction primers were designed against the mRNA sequence of the human, mouse, and rat homologues, if known, using PrimerQuest software (Integrated DNA Technologies) as described previously. 15 Using these primers, a pig polymerase chain reaction product was sequenced and used to design pig-specific primer probe sets using Primer Express 2.0 as described. 15 All primers were obtained from Sigma-Genosys, and the fluorogenic probes 5′-labeled with 6-carboxyfluorescein and 3′-labeled with a minor groove binder were obtained from Applied Biosystems. Primers and probes for quantitative real-time polymerase chain reaction analyses are listed in Table I in the online-only Data Supplement.
Immunoblotting
The preparation of total tissue lysates from snap-frozen liver, separation of proteins by SDS-PAGE (7.5% polyacrylamide gels), and transfer to polyvinylidene fluoride membranes were performed as previously described. 10 Membranes were probed using antibodies against LDLR and α tubulin overnight at 4°C. Secondary antibodies were raised against the IgG of the host species of the primary antibodies, tagged with an infrared fluorophore signaling at either 680 or 800nm (see Major Resources Table in the online-only Data Supplement). Imaging and quantification of immunoblots were performed using the LI-COR Odyssey Fc (LI-COR Biosciences) and LI-COR Image Studio Software 5.0.
Histology
The aortae, stored in 4% paraformaldehyde, were rinsed in 1× PBS. Each aorta was opened longitudinally, immersed in 70% ethanol (10 seconds), and immersed in Sudan IV stain (Sigma-Aldrich; 5 g/L in ethanol:acetone:water, 1:1:1, 15 minutes) with agitation. Samples were destained (15 minutes) with agitation in 80% ethanol. Aortae were splayed and pinned flat on a foam board. Images were obtained with a Canon Rebel digital camera, and digital images downloaded to a computer. Total stained area (all Sudan IV-stained lesion area, including raised lesions) in the full length aorta and raised lesion area in the abdominal aorta (from the aortic hiatus to the aortic bifurcation) were identified visually, traced manually, and the areas calculated using Axiovision software. 20 The percent of total aortic surface area with stained lesions (or raised lesions) were calculated.
A cross-section of the abdominal aorta (1 cm), perpendicular to the direction of blood flow, was obtained from the en face preparation, just proximal to the aortic bifurcation, and embedded in paraffin. Sections (5 µm) were prepared from the distal edge of each segment. A section was stained with hematoxylin and eosin, and an adjacent section was stained with Movat's Pentachrome. Cross-sections were examined by light microscopy to visualize lesion details. A digital image of each section was downloaded to quantify intimal area (including lesions) using Axiovision software.
The left coronary artery and the left anterior descending (LAD) coronary artery were dissected from the paraformaldehyde-fixed heart. Cross-sections of the LAD (1 cm) were obtained 1 and 2 cm distal to the left circumflex bifurcation and paraffin embedded. Sections (5 µm) were prepared from the proximal edge of each segment. A section was stained with hematoxylin and eosin, and adjacent sections were stained with Movat's Pentachrome. LAD sections were also immunostained for CD68 as previously described (see Major Resources Table in the online-only Data Supplement). 21 Sections from the spleen of a pig from a local abattoir were used as a positive control. Peroxidase activity was blocked by incubating sections (5 minutes) with peroxidase block (Dako Envision+ System-HRP [DAB], K4006, Agilent, Santa Clara, CA) followed by blocking for nonspecific protein binding using Protein Block Serum-Free (X0909, Agilent). Primary antibody against pig CD68 (BioRad, MCA2317GA, clone BA4D5 [1 mg/mL]) was diluted 1:1000 and applied overnight at 4°C. Sections were incubated with secondary antibody (Dako Envision+ System-HRP) for 30 minutes at room temperature followed by DAB+ (Dako Envision+ System-HRP) for 7 minutes. Sections were counterstained with hematoxylin (Sigma-Aldrich).
All LAD sections were examined by light microscopy to visualize lesion details. A digital image of each section was used to quantify intimal area (including lesions) and medial area, using Axiovision software. Each aortic and LAD pentachrome-stained section was scored according to the classification of Virmani et al. 22 Classification of sections were no lesion, intimal thickening, intimal xanthoma, pathological intimal thickening, and fibrous cap atheroma. The largest, most advanced plaque type in each section was recorded for between-group comparisons.
Statistical Analyses
For the comparison of ≥3 groups, data were initially tested for normal distribution using the Shapiro-Wilk test and equal variance by F test. If the data were normally distributed, a 1-way ANOVA was performed, followed by a Tukey post hoc test. P<0.05 was considered significant. For data evaluated over time, body weight, and % change LDL-C, a repeated measures ANOVA, followed by a Tukey post hoc test, was performed. If the data were not normally distributed, the nonparametric Kruskal-Wallis 1-way ANOVA on ranks was performed, followed by a Tukey post hoc test. P<0.05 was considered significant.
For the comparison of 2 groups, data were initially tested for normal distribution using the Shapiro-Wilk test and equal variance by F test. If the data were normally distributed, a Student t test was performed. P<0.05 was considered significant. For data not normally distributed, the nonparametric Mann-Whitney rank-sum test was used. P<0.05 was considered significant. All statistical analyses were performed using SigmaPlot 14.0 or GraphPad Prism 7.
Results
Body Weight, Clinical Chemistry, and Pharmacokinetics
LDLR
+/− pigs (n=12) and LDLR −/− pigs (n=12) were fed an HFHC diet for 14 days. Pigs of each genotype were then subdivided into groups receiving placebo (n=4), BemA at 120 mg/d (n=4), or BemA at 240 mg/d (n=4) in addition to the HFHC diet for an additional 160 days ( Figure 1A ).
Most pigs gained weight similarly (≈85 g/d) for 160 days ( Figure 1B and 1C) . LDLR +/− pigs treated with BemA at 120 mg/d gained weight more slowly (64 g/d), such that at 160 days, they weighed 15% less than the other 5 groups. The reason for this difference is unapparent because caloric intake was the same and all pigs were otherwise healthy. Plasma levels of urea, creatinine, total bilirubin, alanine transaminase, and creatine kinase were measured at days 0, 28, and 160 (Tables II and III in the online-only Data Supplement). All measurements were normal, and there were no differences among placebo, BemA at 120 mg/d, or BemA at 240 mg/d in either genotype or with time.
Plasma pharmacokinetic analyses were performed after a single dose of BemA (120 or 240 mg) in drug-naive pigs fed the HFHC diet for 2 weeks (Figure 1D-1F) . Parameters for maximal concentration, time of maximal concentration, area under the concentration/time curve for 24 hours, and half life did not differ between genotypes. The combined genotype data for time of maximal concentration and half life were similar at 120 and 240 mg doses. In both genotypes, maximal concentration was ≈2-fold higher at 240 mg compared with 120 mg, and the area under the concentration/time curve for 24 hours was ≈2-fold higher at 240 mg compared with 120 mg (Figure 1G ). At maximal concentration, plasma concentrations of the main active metabolite of BemA, ESP15228, were <3% of the parent compound, and pharmacokinetic parameters did not differ between doses or genotypes (data not shown).
Plasma Lipids and Lipoproteins
BemA significantly reduced plasma cholesterol in both rodents and humans, so we first assessed plasma lipids in treated pigs. Total plasma cholesterol in LDLR +/− pigs fed the HFHC diet with placebo initially increased from 3.95 to 4.75 mmol/L and subsequently remained stable ( Figure IA in the online-only Data Supplement). BemA at 120 and 240 mg/d reduced total plasma cholesterol by 17% and 26%, respectively, from baseline to 160 days, such that at 160 days total plasma cholesterol was 32% and 40% lower than placebo (Figure 2A) .
LDL-C concentrations increased in LDLR +/− pigs fed the HFHC diet with placebo for the first 28 days and subsequently remained stable ( Figure IB in the online-only Data Supplement). BemA at 120 and 240 mg/d reduced LDL-C 32% and 42%, respectively, from baseline to 160 days, such that at 160 days, LDL-C was 51% and 61% lower than placebo ( Figure 2C) .
In LDLR −/− pigs fed the HFHC diet plus placebo, total plasma cholesterol initially increased from 19.9 to 21.0 mmol/L and increased more slowly through 160 days ( Figure  IIA in the online-only Data Supplement). BemA at 120 and 240 mg/d reduced total plasma cholesterol by 12% and 15%, respectively, from baseline to 160 days, such that at 160 days, total plasma cholesterol was 23% and 27% lower than placebo ( Figure 2B ).
LDL-C concentrations increased in LDLR −/− pigs fed the HFHC diet plus placebo from 18.1 to 18.6 mmol/L through 160 days ( Figure IIB in the online-only Data Supplement). BemA at 120 and 240 mg/d reduced LDL-C by 16% and 18%, respectively, from baseline to 160 days, such that at day 160 LDL-C was 27% and 29% lower than placebo ( Figure 2D pigs ( Figure 2G ), reflecting increased cholesterol synthesis in homozygotes, similar to observations in human familial hypercholesterolemia. 23 At both 28 and 160 days, BemA treatment decreased lathosterol concentrations in both LDLR +/− (−50% to −51%) and LDLR −/− (−43% to −55%) pigs. Both doses showed similar reductions that persisted when lathosterol was expressed as a ratio to total cholesterol ( Figure 2H ). Lower lathosterol levels in BemA-treated pigs are consistent with BemA-induced inhibition of hepatic cholesterol synthesis. Together with the reductions of LDL-C in both genotypes, these results indicate that BemA was active in liver after its conversion to the CoA derivative by liver-specific long-chain acyl-CoA synthetase-1. mRNA expression of the pig enzyme (SLC27A) was confirmed to be liver-specific as shown in Figure IV in the online-only Data Supplement.
In LDLR +/− and LDLR −/− pigs, plasma triglyceride concentrations were low at day 160 (0.27 and 0.29 mmol/L, respectively; Figure 3A and 3B). The HFHC diet and BemA had no significant effect on plasma triglycerides ( Figure 3A and 3B) . 
Plasma Glucose and Insulin
In contrast to studies in rodents, there were no consistent differences in fasting plasma glucose or insulin among genotypes or treatment groups ( Figure 3C-3F) . In LDLR +/− pigs at 160 days, plasma glucose was ≈20% (not significant [N.S.]) lower in pigs treated with BemA compared with placebo ( Figure 3C ). Conversely, in LDLR −/− pigs, plasma glucose increased 10% to 18% (N.S.) with . E and F, Plasma was subjected to fast protein liquid chromatography at day 160 (n=3/ group). Cholesterol was measured in eluted fractions, and the mean concentration in each fraction is shown. LDL-C area under the curve calculations are shown in Figure IV in the online-only Data Supplement. G, Plasma lathosterol concentrations, and (H), ratio of plasma lathosterol:plasma cholesterol concentrations at days 28 and 160 (n=3-4/group). Data are presented as mean±SEM. *P<0.05 vs placebo, repeated measures 2-way ANOVA with post hoc Tukey test. Different lower-case letters indicate significant differences; ANOVA with post hoc Tukey test (P<0.05). **P<0.05 vs placebo; Student t test. ***P<0.05 vs placebo; Mann-Whitney rank-sum test. N.S. indicates no significant differences; ANOVA.
BemA treatment compared with placebo ( Figure 3E ). There was no difference in fasting plasma insulin concentrations among genotypes or treatment groups ( Figure 3D and 3F) .
Liver Lipids
BemA reduced hepatic lipids in rodents; therefore, we measured hepatic cholesterol and triglyceride concentrations. Compared with LDLR +/− placebo pigs fed the HFHC diet, liver total cholesterol, free cholesterol, and cholesteryl ester in LDLR −/− placebo pigs fed the HFHC diet were 1.8-, 1.6-, and 2.9-fold higher, respectively ( Figure 3G and 3H) . In either genotype, BemA had no significant effect on liver total cholesterol, free cholesterol, or cholesteryl ester at either dose. BemA at 240 mg/d modestly reduced cholesteryl ester (≈10%; N.S.) in both genotypes. Liver triglycerides were 1.2-fold higher in LDLR −/− placebo pigs compared with LDLR +/− placebo pigs but were unaffected by BemA treatment.
Liver Gene and Protein Expression
To understand the molecular mechanisms underlying the BemA-mediated LDL-C reduction, select hepatic gene expression and protein levels were examined ( Figure 4 ). As predicted, liver LDLR mRNA and LDLR protein were not detectable in LDLR −/− pigs ( Figure 4A-4C ). In LDLR +/− pigs, administration of BemA at both 120 and 240 mg/d modestly decreased LDLR mRNA (N.S.) compared with placebo but had no effect on LDLR protein. We anticipated that BemA treatment would increase LDLR mRNA in LDLR +/− pigs because BemA is an inhibitor of hepatic cholesterol synthesis. We speculate that with long-term BemA treatment, hepatic cholesterol homeostasis may have reached a new steady state, such that LDLR mRNA returned to baseline levels. In support of this concept, in a small number of LDLR +/− pigs consuming the same diet and treated with 240 mg/d of BemA for 6 weeks, hepatic LDLR mRNA increased 1.5-fold compared with placebo ( Figure 4D ).
Liver mRNA for SREBF2 and other SREBF2 target genes, HMGCR, PCSK9, and NPC1L1 were generally unaffected by genotype or BemA treatment ( Figure 4E-4H) . SREBF2, HMGCR, and NPC1L1 trended higher in LDLR −/− pigs compared with LDLR +/− pigs, consistent with increased cholesterol synthesis in homozygotes; however, these differences were not significant. In LDLR −/− pigs, BemA at 120 mg/d increased PCSK9 mRNA 2-fold compared with placebo although no effect was observed at the 240 mg/d dose ( Figure 4G ). The explanation for this observation is unknown. ApoB (APOB), SREBF1c, CYP7A1, MTTP, and ABCA1 expressions were unaffected by genotype or BemA treatment ( Figure 4I ).
Aortic Atherosclerosis
The significant reduction in LDL-C with BemA treatment suggests that BemA may affect atherosclerosis development in LDLR-deficient pigs. In these pigs, aortic atherosclerosis developed in a characteristic pattern, 16, 17 with raised lesions primarily in the abdominal aorta and nonraised lesions in the ascending aorta and aortic arch ( Figure 5C ). Because there was no significant dose-dependent effect with respect to LDL-C or lesion reductions, lesion data from both doses were combined. In LDLR +/− pigs, BemA treatment decreased total lesion area 58% and raised lesion area 58% compared with placebo ( Figure 5B and 5C) .
In aortae from LDLR −/− pigs, BemA at 120 and 240 mg/d reduced total and raised lesions compared with placebo ( Figure 5D ; Figure Figure 5F ). Again, because there was no significant dose-dependent difference with respect to LDL-C or lesion reductions, lesion data from both doses were combined. BemA treatment decreased total lesion area 47% and raised lesion area 50% ( Figure 5E and 5F).
To further characterize the aortic atherosclerotic plaques, cross-sections of abdominal aorta, obtained at a standard distance proximal to the aortic bifurcation, were stained with Movat's pentachrome ( Figure 5A and 5D) . In LDLR +/− pigs, aortic plaque morphology, typed according to the human classification of Virmani et al, 22 was primarily intimal thickening, consisting of mainly smooth muscle cells, extracellular matrix, and intimal xanthomas, with foam cell infiltration in the intimal layer (Figure 5A ). In LDLR −/− pigs, in addition to intimal thickening and xanthomas, a large number of lesions showed pathological intimal thickening (Figure 5D ). These lesions had readily apparent extracellular lipid, no areas of necrosis, but a smooth muscle cell-containing fibrous cap overlying areas of lipid ( Figure 5D ). Similar lesions have been observed in LDLR −/− pigs. 16 Cross-sectional measurements revealed that intimal plaque area was ≈10-fold greater in LDLR −/− pigs compared with LDLR +/− pigs. BemA reduced mean intimal areas, including lesions, in both LDLR +/− and LDLR −/− pigs although differences were not statistically significant (data not shown). Within each genotype, macroscopic analyses of the largest raised lesion in each abdominal aortic section did not reveal significant BemA-induced differences in plaque classification (data not shown).
Similar to humans, pigs develop coronary atherosclerosis. Atherosclerosis in the LAD coronary artery was assessed in sections obtained at standardized distances distal to the origin of the circumflex artery. Sections were stained with Movat's pentachrome to permit assessment of intimal and medial areas and plaque classification. Representative LAD cross-sections and higher magnification of representative lesions are shown in Figure 6A doses (−40%). Morphological analyses of the largest lesion in each section demonstrated that BemA treatment decreased the percent of lesions classified as intimal xanthomas (38% versus 14%), increased the percent of lesions classified as intimal thickening, and increased the number of sections with no lesions ( Figure 6C ). The improvement in lesion class was significant for the combined dose data ( Figure 6C ). Histological analysis revealed that macrophage content of lesions in LDLR +/− pigs was low and unquantifiable ( Figure VII in the online-only Data Supplement).
In LDLR −/− pigs, BemA treatment reduced LAD intimal area, including plaques, 70% at 240 mg/d, but not at 120 mg/d (−12%) or when doses were combined (−42%; N.S.; Figure 6E ). Medial area was decreased 22% at 240 mg/d compared with placebo. The intimal/medial area ratio was reduced by BemA at 120 mg/d (−28%; N.S.), at 240 mg/d (−70%), and by combining the data of both doses (−48%; Figure 6E ). Morphological analyses of the largest lesion in each section showed that BemA treatment reduced the percentage of lesions classified as either pathological intimal thickening or fibrous cap atheroma and increased the percent classified as intimal xanthomas or intimal thickening (Figure 6F ). In placebotreated pigs, 84% of sections had at least 1 lesion classified as more advanced, whereas only 50% of lesions were classified as such in BemA-treated LDLR −/− pigs. The improvement in lesion class was significant for the combined dose data 
Discussion
The ability of the novel ATP-citrate lyase inhibitor BemA to reduce plasma LDL-C long-term and attenuate atherosclerosis in a large animal model that recapitulates human lipoprotein metabolism and disease pathophysiology had not been established. In the present study, BemA treatment of LDLRdeficient miniature pigs for 160 days decreased LDL-C up to 63% in LDLR +/− animals and up to 29% in LDLR −/− animals. BemA treatment did not affect plasma triglycerides, HDL-C, glucose, and insulin. In both LDLR +/− and LDLR −/− pigs, BemA treatment attenuated atherosclerosis development up to 58% in the aorta and up to 45% in the LAD coronary artery. The drug was well tolerated.
In LDLR +/− pigs fed the HFHC diet, BemA significantly decreased LDL-C as early as 28 days of treatment and was sustained up to 160 days. Doubling the dose did not significantly improve LDL-C lowering, an effect also reported in hypercholesterolemic patients treated with similar doses of BemA. 24, 25 An analogous observation was reported with statin treatment of hypercholesterolemic patients, where doubling the statin dose improves the percent LDL-C reduction by only 6% to 8%. 26 The mechanism underlying BemA-induced LDL-C reduction is not readily apparent. We anticipated that BemA-mediated cholesterol synthesis inhibition would decrease hepatic cholesterol concentrations and upregulate hepatic LDLR expression in heterozygotes through the SREBP2 pathway. 11 Although BemA decreased cholesterol synthesis, as evidenced by lower plasma lathosterol levels, treatment did not affect hepatic cholesterol content or SREBF2 expression, and LDLR mRNA and LDLR protein expressions were unchanged. The expressions of other hepatic SREBP2 target genes, including HMGCR, PCSK9, and NPC1L1, were also unaffected. One potential explanation is that at 160 days of treatment, hepatic cholesterol metabolism has reached a new steady state, such that hepatic cholesterol and LDLR expressions have returned to pretreatment levels. In support of this concept, BemA treatment of LDLR +/− pigs consuming the same diet for 6 weeks increased hepatic LDLR mRNA 1.5-fold compared with placebo. Another possibility is that BemA inhibited hepatic production of very-low-density lipoprotein and LDL, a mechanism for LDL reduction described previously in pigs treated with statins. 14, 15 ApoB kinetic studies are required to test these possibilities.
The effect of BemA in LDLR −/− pigs was unanticipated because of the complete LDLR deficiency. However, this group was included based on the LDL-C-lowering response in BemA-treated Ldlr −/− mice. 10 In LDLR −/− pigs, LDL-C was up to 29% lower with BemA treatment compared with placebo. Although the percent lowering of LDL-C was less than that observed in LDLR +/− pigs, the absolute LDL-C reduction in treated LDLR −/− pigs was much larger (≈5.4 versus ≈1.6 mmol/L). We observed no dose response in LDLR −/− pigs, suggesting that the mechanism for LDL-C lowering in homozygotes may have been maximized at 120 mg/d. Although cholesterol synthesis was higher in LDLR −/− pigs, BemA treatment decreased endogenous cholesterol synthesis to a similar extent as in LDLR +/− pigs, which is consistent with the similar pharmacokinetic profiles of BemA in both genotypes. As was observed in heterozygotes, BemA treatment of LDLR −/− pigs did not affect hepatic cholesterol concentrations, and gene expression analyses did not provide further mechanistic insights. One obvious possibility is that BemA decreased hepatic secretion of very-low-density lipoprotein and LDL apoB. Alternatively, BemA may upregulate non-LDLR-mediated LDL clearance. ApoB kinetic studies would provide initial insights into either of these hypotheses.
BemA treatment had little effect on plasma triglycerides, HDL-C, glucose, and insulin in either genotype although differences may have been masked by the small sample size. However, our results for these parameters mirror the effect of BemA in clinical studies of patients with hypercholesterolemia (reviewed in Ref 12) . In contrast, studies in BemAtreated rodents consistently demonstrated reduced fatty acid synthesis, liver triglycerides, liver cholesterol, hepatic verylow-density lipoprotein secretion, plasma triglycerides, and adiposity, as well as improved glucose tolerance. [8] [9] [10] 27 Reasons for these differences are not entirely clear. In the present study, liver triglyceride content in LDLR-deficient pigs is <10% of that in high-fat diet-fed mice. 10 It is possible that compared with rodents, rates of hepatic de novo fatty acid synthesis are low in pigs and in humans studied to date, such that blocking fatty acid synthesis would have little effect on triglyceride metabolism. Furthermore, BemA had little effect on hepatic cholesterol content in LDLR-deficient pigs, whereas in highfat diet-fed mice BemA decreased hepatic cholesterol ≈50%. This may be related to the lower liver cholesterol content in LDLR-deficient pigs (<40%) compared with high-fat diet-fed mice. 10 It is possible that BemA inhibition of hepatic cholesterol synthesis in pigs is sufficient to influence the hepatic cholesterol regulatory pool but not cholesterol mass within the whole liver.
The development of LDLR-deficient Yucatan miniature pigs, a model of human familial hypercholesterolemia, has provided a versatile model for the study of atherosclerosis. 16 In the present study, we examined the impact of BemA on atherosclerosis in both LDLR +/− and LDLR −/− minipigs fed a high-fat diet-containing 0.2% cholesterol. We anticipated that 0.2% cholesterol would be sufficient to induce atherosclerosis in both genotypes and reasoned that a high, nonphysiological level of dietary cholesterol (1%-2%) might mask or overwhelm the efficacy of cholesterol-lowering drugs, including Different upper-case letters indicate significant differences; Kruskal-Wallis 1-way ANOVA on ranks, followed by a Tukey post hoc test. **P<0.05 vs placebo, Student t test. ***P<0.05 vs placebo, Mann-Whitney rank-sum test. N.S. indicates no significant differences; ANOVA. n.s. indicates no significant differences, Kruskal-Wallis 1-way ANOVA on ranks.
BemA. Indeed, aortic atherosclerosis, as well as LAD coronary artery atherosclerosis, developed in both LDLR +/− and LDLR −/− pigs. As anticipated, atherosclerosis in LDLR −/− pigs was more advanced than in LDLR +/− pigs. The extent of lesion development and class of lesions in the aorta and coronary arteries were similar to those previously reported in LDLR-deficient pigs and in D374Y PCSK9 transgenic pigs 16, 17 even though these studies used diets with higher dietary cholesterol (1%-2%).
In both LDLR +/− and LDLR −/− pigs, BemA treatment markedly decreased total and raised lesion area in the aorta. In the LAD, BemA reduced intimal/medial area and shifted the classification of lesions to less advanced lesions. This robust improvement in atherosclerosis is most likely because of the large, sustained reductions in LDL-C in both genotypes compared with placebo. However, we could not exclude a direct effect of BemA on cells within the arterial wall. [8] [9] [10] 27 Lesion macrophage content was low, as previously reported in atherosclerotic pigs. 21 In LDLR +/− pig coronary lesions, macrophage content was too low to be quantified, and in LDLR −/− pigs, the low macrophage content was unaffected by BemA. Attenuation of atherosclerosis in both genotypes did not seem to be dose responsive, consistent with the observation that LDL-C reductions by BemA at the 2 doses were not statistically different. It is possible that with a larger sample size, a dose-response relationship would emerge. The effect of BemA on atherosclerosis in LDLR −/− pigs was not anticipated. However, the significant BemA-induced reduction in LDL-C translated into a significant attenuation of atherosclerosis. Comparatively, previous reports demonstrated that atorvastatin (3 mg/kg per day) treatment of LDLR +/− pigs decreased aortic and coronary artery lesion area, 28 and pitivastatin (40 mg/d) treatment of LDLR −/− pigs attenuated coronary lesion size and severity. 29 There are several limitations to the present study. Although the number of pigs studied was similar to previous reports, 16, 17, 30 the sample size may have been insufficient to achieve statistical significance for some parameters at each dose tested. However, combining the atherosclerosis data for both doses, justified by the lack of dose-specific differences in plasma LDL-C, allowed for statistically significant treatment effects to emerge. ApoB kinetic studies are required to provide insight into the mechanism underlying plasma LDL-C reductions, especially in LDLR −/− pigs. Although BemA attenuated early lesion development in LDLR +/− pigs, a longer diet and treatment time would be required to assess BemA-mediated effects on more advanced lesions in this genotype. Differences in experimental outcomes between males and females were not apparent; however, the numbers of animals studied were insufficient to assess sex effects. Finally, it will be important to use an intervention protocol to examine the impact of BemA on lesion regression.
In conclusion, treatment of both LDLR +/− and LDLR −/− pigs with BemA significantly decreased plasma LDL-C and attenuated aortic and coronary atherosclerosis. These studies have several important implications. First, they underscore the value of LDLR-deficient Yucatan minipigs in preclinical evaluation of therapeutics that impact lipoprotein metabolism and atherosclerosis. Second, the efficacy of BemA in LDLR −/− pigs implies that attenuated secretion of hepatic apoB100-containing lipoproteins contributes to BemA-induced LDL-C reductions and that BemA use could expand beyond the anticipated target patient population and serve as adjunct therapy for patients with homozygous familial hypercholesterolemia. Third, they fully support the pursuit of LDL-C lowering as a BemA therapeutic indication, as well as ongoing BemA cardiovascular disease outcome trials in patients.
